Antibody Fc Mutants with Ablated Effector Functions

Abstract

Antibody and other Fc-containing molecules with variations in the Fc region reduce binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.

What is claimed: 
     
         1 . A method for treating a condition in a subject or patient characterized by the migration and concentration of macrophages, comprising administering to the subject or patient an Fc-containing molecule having decreased affinity for at least FcγRI and FcγRIIa as compared to an Fc-containing molecule with a wildtype Fc domain, comprising an antibody Fc domain with a mutated IgG2 constant region comprising the mutations V234A, G237A, P238S, H268A, V309L, A330S and P331S, wherein residue numbering is according to the EU numbering system 
     
     
         2 . The method of  claim 1 , wherein the patient is an unborn infant and the Fc-containing molecule is administered to the mother of the patient. 
     
     
         3 . The method of  claim 1 , wherein the Fc-containing molecule is an antibody or a Fc fusion protein. 
     
     
         4 . The method of  claim 1 , wherein the Fc domain of the Fc-containing molecule with the mutated IgG2 constant region is capable of specifically binding FcRn.